X4 Pharmaceuticals, Inc. Common Stock
Symbol: XFOR (NASDAQ)
1.80
▼ (-1.58%) -0.029
Company Description:
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Key Stats
- Today's Open: $1.81
- Today's High: $1.975
- Today's Low: $1.665
- Today's Volume: 1.55M
- Yesterday Close: $1.83
- Yesterday High: $2.25
- Yesterday Low: $1.51
- Yesterday Volume: 15.76M
- Last Min Volume: 600
- Last Min High: $1.804
- Last Min Low: $1.801
- Last Min VWAP: $1.804
Company Profile
- Name: X4 Pharmaceuticals, Inc. Common Stock
- Website: https://www.x4pharma.com
- Listed Date: 2017-11-16
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001501697
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $13.14M
- Round Lot: 100
- Outstanding Shares: 7.18M
- Asset Type: CS
RECENT FILINGS FOR XFOR
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-07-18 | SCHEDULE 13G/A | View |
| 2025-07-03 | 4 | View |
| 2025-06-23 | 8-K | View |
| 2025-06-23 | 424B5 | View |
| 2025-06-11 | 8-K | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-03 | 3 | View |
| 2025-06-03 | 4/A | View |
| 2025-05-20 | 4 | View |
| 2025-05-01 | 10-Q | View |
| 2025-05-01 | 8-K | View |
| 2025-04-25 | DEF 14A | View |
| 2025-04-25 | DEFA14A | View |
| 2025-04-24 | 8-K | View |
| 2025-04-18 | 8-K | View |
Latest News on XFOR